^
Association details:
| Biomarker: | IDH2 mutation + TMB-L |
|---|---|
| Cancer: | Glioma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase II trial evaluating nivolumab in patients with recurrent IDH-mutant gliomas with and without hypermutation phenotype.
Published date:
05/25/2023
Excerpt:
As of May 2022, 17 patients were enrolled to NHMP cohort and 15 were treated (TMB˂5 mut/Mb)...Six out of 15 (40%) patients were progression free at 6 months...Nivolumab is well tolerated and has demonstrated efficacy in a cohort of patients with recurrent IDH-mutant gliomas with low TMB.
DOI:
https://meetings.asco.org/abstracts-presentations/223242
Trial ID:
